Updated clinical and biological information from the two-stage phase II study of imatinib mesylate in subjects with relapsed/refractory neuroblastoma

References

• Garaventa A, Parodi S, De Bernardi B, Dau D, Manzitti C, Conte M, Casale F, Viscardi E, Bianchi M, D’Angelo P, et al. Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry. Eur J Cancer. 2009;45(16):2835–2842. doi:10.1016/j.ejca.2009.06.010.
   PubMed Web of Science ®Google Scholar
• London WB, Castel V, Monclair T, Ambros PF, Pearson AD, Cohn SL, Berthold F, Nakagawara A, Ladenstein RL, Iehara T, et al. Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the international neuroblastoma risk group project. J Clin Oncol. 2011;29(24):3286–3292. doi:10.1200/JCO.2010.34.3392.
   PubMed Web of Science ®Google Scholar
• Moreno L, Rubie H, Varo A, Le Deley MC, Amoroso L, Chevance A, Garaventa A, Gambart M, Bautista F, Valteau-Couanet D, et al. Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials. Pediat Blood Cancer. 2017;64(1):25–31. doi:10.1002/pbc.26192.
   PubMed Web of Science ®Google Scholar
• Calafiore L, Amoroso L, Della Casa Alberighi O, Luksch R, Zanazzo G, Castellano A, Podda M, Dominici C, Haupt R, Corrias MV, et al. Two-stage phase II study of imatinib mesylate in subjects with refractory or relapsing neuroblastoma. Ann Oncology. 2013;24(5):1406–1413. doi:10.1093/annonc/mds648.
   PubMed Web of Science ®Google Scholar
• Borg C, Terme M, Taieb J, Menard C, Flament C, Robert C, Maruyama K, Wakasugi H, Angevin E, Thielemans K, et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest. 2004;114(3):379–388. doi:10.1172/JCI21102.
   PubMed Web of Science ®Google Scholar
• Menard C, Blay JY, Borg C, Michiels S, Ghiringhelli F, Robert C, Nonn C, Chaput N, Taieb J, Delahaye NF, et al. Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. Cancer Res. 2009;69(8):3563–3569. doi:10.1158/0008-5472.CAN-08-3807.
   PubMed Web of Science ®Google Scholar
• Bellora F, Dondero A, Corrias MV, Casu B, Regis S, Caliendo F, Moretta A, Cazzola M, Elena C, Vinti L, et al. Imatinib and nilotinib off-target effects on human NK cells, monocytes, and M2 macrophages. J Immunol. 2017;199(4):1516–1525. doi:10.4049/jimmunol.1601695.
   PubMed Web of Science ®Google Scholar
• Matthay KK, Maris JM, Schleiermacher G, Nakagawara A, Mackall CL, Diller L, Weiss WA. Neuroblastoma. Nat Rev Dis Prim. 2016;2(16078). doi:10.1038/nrdp.2016.78.
   PubMedGoogle Scholar
• Delahaye NF, Rusakiewicz S, Martins I, Menard C, Roux S, Lyonnet L, Paul P, Sarabi M, Chaput N, Semeraro M, et al. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med. 2011;17(6):700–707. doi:10.1038/nm.2366.
   PubMed Web of Science ®Google Scholar
• Rusakiewicz S, Perier A, Semeraro M, Pitt JM, Pogge Von Strandmann E, Reiners KS, Aspeslagh S, Piperoglou C, Vely F, Ivagnes A, et al. NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients. Oncoimmunology. 2017;6(1):e1137418. doi:10.1080/2162402x.2015.1137418.
   PubMed Web of Science ®Google Scholar
• Semeraro M, Rusakiewicz S, Minard-Colin V, Delahaye NF, Enot D, Vely F, Marabelle A, Papoular B, Piperoglou C, Ponzoni M, et al. Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients. Sci Translat. 2015;7(283):283ra55. doi:10.1126/scitranslmed.aaa2327.
   PubMedGoogle Scholar
• Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10(1):1–10. doi:10.1016/0197-2456(89)90015-9.
   PubMedGoogle Scholar
• Bryant J, Day R. Incorporating toxicity considerations into the design of two-stage phase II clinical trials. Biometrics. 1995;51(4):1372–1383. doi:10.2307/2533268.
   PubMed Web of Science ®Google Scholar
• Scaruffi P, Morandi F, Gallo F, Stigliani S, Parodi S, Moretti S, Bonassi S, Fardin P, Garaventa A, Zanazzo G, et al. Bone marrow of neuroblastoma patients shows downregulation of CXCL12 expression and presence of IFN signature. Pediat Blood Cancer. 2012;59(1):44–51. doi:10.1002/pbc.23339.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods. 2001;25(4):402–408. doi:10.1006/meth.2001.1262.
   PubMed Web of Science ®Google Scholar
• Amoroso L, Erminio G, Makin G, Pearson ADJ, Brock P, Valteau-Couanet D, Castel V, Pasquet M, Laureys G, Thomas C, et al. Topotecan-vincristine-doxorubicin in stage 4 high-risk neuroblastoma patients failing to achieve a complete metastatic response to rapid COJEC: A SIOPEN study. Cancer Res Treat. 2018;50(1):148–155. doi:10.4143/crt.2016.511.
   PubMed Web of Science ®Google Scholar
• Di Giannatale A, Dias-Gastellier N, Devos A, Mc Hugh K, Boubaker A, Courbon F, Verschuur A, Ducassoul S, Malekzadeh K, Casanova M, et al. Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a european innovative therapies for children with cancer-SIOP-european neuroblastoma study. Eur J Cancer. 2014;50(1):170–177. doi:10.1016/j.ejca.2013.08.012.
   PubMed Web of Science ®Google Scholar
• Moreno L, Caron H, Geoerger B, Eggert A, Schleiermacher G, Brock P, Valteau-Couanet D, Chesler L, Schulte JH, De Preter K, et al. Accelerating drug development for neuroblastoma - new drug development strategy: an innovative therapies for children with cancer, european network for cancer research in children and adolescents and international society of paediatric oncology Europe neuroblastoma project. Expert Op Drug Disc. 2017;12(8):801–811. doi:10.1080/17460441.2017.1340269.
   PubMed Web of Science ®Google Scholar
• Pesce S, Tabellini G, Cantoni C, Patrizi O, Coltrini D, Rampinelli F, Matta J, Vivier E, Moretta A, Parolini S, et al. B7-H6-mediated downregulation of NKp30 in NK cells contributes to ovarian carcinoma immune escape. Oncoimmunology. 2015;4(4):e1001224. doi:10.1080/2162402x.2014.1001224.
   PubMed Web of Science ®Google Scholar
• Bellora F, Castriconi R, Dondero A, Carrega P, Mantovani A, Ferlazzo G, Moretta A, Bottino C. HumanNK cells and NK receptors. Immunol Lett. 2014;161(2):168–173. doi:10.1016/j.imlet.2013.12.009.
   PubMed Web of Science ®Google Scholar
• Bottino C, Dondero A, Bellora F, Moretta L, Locatelli F, Pistoia V, Moretta A, Castriconi R. Natural killer cells and neuroblastoma: tumor recognition, escape mechanisms, and possible novel immunotherapeutic approaches. Front Immunol. 2014;5:56. doi:10.3389/fimmu.2014.00056.
   PubMed Web of Science ®Google Scholar
• Vassal G, Kearns P, Blanc P, Scobie N, Heenen D, Pearson A. Orphan drug regulation: A missed opportunity for children and adolescents with cancer. Eur J Cancer. 2017;84:149–158. doi:10.1016/j.ejca.2017.07.021.
   PubMed Web of Science ®Google Scholar
• Amoroso L, Haupt R, Garaventa A, Ponzoni M. Investigational drugs in phase II clinical trials for the treatment of neuroblastoma. Exp Op Iinvestigat Drugs. 2017;26(11):1281–1293. doi:10.1080/13543784.2017.1380625.
   PubMed Web of Science ®Google Scholar